The family last year offered $10 million for information leading to an arrest, Toronto’s Globe and Mail Then, in early 2018, Apotex CEO Jeremy Desai stepped down amid allegations he stole trade secrets from a girlfriend who previously served as an executive at global generics giant Teva Pharmaceutical.Desai denied the allegations and sued back, Canadian news magazine Maclean’s Last year, Apotex sold its businesses in five European countries to Aurobindo for €74 million ($83 million). Last year, Apotex sold its businesses in five European countries to Aurobindo for €74 million ($83 million). ©2020 FOX News Network, LLC. Use a + to require a term in results and - to All rights reserved. 3 Speen Street, Suite 300, Framingham, MA 01701 Real-time quotes provided by This material may not be published, broadcast, rewritten, or redistributed. ©2020 FOX News Network, LLC. Nearly a year and a half after the death of Apotex’s founder and CEO and his wife, the company is reportedly mulling a sale. Quotes delayed at least 15 minutes. exclude terms.The family in control of Canadian generics maker Apotex is weighing a sale, Bloomberg reports. New technology could create a substantial job-cut in the banking industry.
All rights reserved. The company employs more than 10,000 people in R&D, manufacturing and distribution worldwide. Apotex has yet to confirm the reports that it is … Amidst recent recalls over a suspected carcinogen used in the over-the-counter acid reflux medication Zantac, the On Wednesday, the FDA released the results of preliminary tests of safer, carcinogen-free antacid alternatives, including the likes of Pepcid (famotidine), Tagamet (cimetidine), Nexium (esomeprazole), Prevacid (lansoprazole) and Prilosec (omeprazole), all of which were found to have no traces of the potentially cancer-causing agent NDMA, unlike the popular OTC antacid drug Zantac.Generic drugmakers Perrigo, Sanofi, Novartis' Sandoz division and Apotex have all rushed to recall the top antacid on the market today, Zantac, which has been found to contain a suspected carcinogen for years now, unbeknownst to the FDA.The agency’s announcement comes on the heels of generic Zantac drugmakers voluntarily recalling their products from pharmaceutical store shelves, however, CVS, Walgreens, Walmart and Rite Aid have all suspended sales of Zantac until further notice “out of an abundance of caution,” according to a It’s important to note, however, that “NDMA may cause cancer only after exposure to high doses over a long period of time,” Harvard Health reports, and that makers of the generic version of Zantac have yet to receive any reports of adverse reactions to the NDMA-infused heartburn drug.Meanwhile, NDMA has also been found in high blood pressure medication as well, including the likes of losartan and valsartan, both of which were recalled by the FDA on Oct. 15.Quotes delayed at least 15 minutes. According to Bloomberg, which cited anonymous sources close to the matter, the Canadian generic drugmaker has been in discussions with several interested parties about a deal that could be worth up to $3 billion. ATM fees now at rate of $4.72 for an out-of-network withdrawal, an increase of 33 percent. In late 2017, Sherman and his wife were found dead in Toronto, but the killings remain a mystery. (Pixabay)Subscribe to FiercePharma to get industry news and updates delivered to your inbox.After Apotex founder's murder, family weighs sale worth up to $3B: report© 2020 Questex LLC. Fox Business Briefs: Stores are dropping Zantac from their shelves over risks it contains a substance that could cause cancer. It's focused on generics, biosimilars, APIs and innovative pharma products.Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.Enclose phrases in quotes. Real-time quotes provided by This material may not be published, broadcast, rewritten, or redistributed. Apotex had not responded to a FiercePharma request for comment by press time.Sale discussions are the latest development in a volatile period for the company. Apotex Inc. is exploring a sale as some major pharmaceutical companies and investors expressed interest in the closely held Canadian drugmaker, according to … Apotex said the sale would allow it to focus on the Americas, where demand remains strong. Discussions are preliminary, the news service's sources said, but if the family decides to sell, the deal could fetch $3 billion.
Generic drugmakers Perrigo, Sanofi, Novartis' Sandoz division and Apotex have all rushed to recall the top antacid on the market today, Zantac, which has been found to … All rights reserved. It’s been a tumultuous year and a half at Canadian generics maker Apotex, and now the company is weighing a sale, Bloomberg Sherman’s family now controls the drugmaker and has hired a financial adviser to review its options, Bloomberg reports.